Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Genentech and Takeda Oncology.
Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based
Compared with standard chemotherapy, ALK inhibitors have afforded patients with advanced ALK-positive non-small cell lung cancer (NSCLC) increased treatment options and improved efficacy, and have become the standard of care. However, the development of resistance to ALK inhibitor therapy and central nervous system (CNS) metastases remain significant clinical challenges. In this activity, Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better Outcomes, you will explore the treatment approach, sequencing, and management decisions recommended by expert faculty, David R. Gandara, MD, and Sai-Hong Ignatius Ou, MD, PhD, as they present their perspectives on applying recent trial findings to help you in providing personalized and optimal care for your patients. Case studies are used to illustrate these practices in a real-world setting. You will learn about the most current and novel molecular testing methodologies for detecting ALK rearrangements, appraise the field of currently approved ALK inhibitors, and consider those soon to enter the field.
For busy oncologists focused on the management of complex patients with advanced ALK-positive NSCLC, this activity provides you with an up-to-date perspective on the evolving practice paradigm to enable you to bring personalized medicine to the care of your patients.
Instructions for This Activity and Receiving Credit
This educational activity is directed toward pathologists and oncologists interested in the management of patients with cancer. Fellows, residents, nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of patients with cancer are also invited to participate.
At the conclusion of this activity, you should be better prepared to:
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Disclosure: Grant/Research Support: AstraZeneca/Medi, Genentech; Consultant: AstraZeneca, Celgene, Genentech, Guardant Health, Lilly, Liquid Genomics/NANT, CellMax Life
Sai-Hong Ignatius Ou, MD, PhD
Chao Family Comprehensive Cancer Center
University of California School of Medicine
Disclosure: Consultant: Genentech, AstraZeneca, Takeda/Ariad, Foundation Medicine, Pfizer; Speakers Bureau: Genentech, AstraZeneca, Merck, Takeda/FMI
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018